Cadrenal Therapeutics Files Q1 2025 10-Q
Ticker: CVKD · Form: 10-Q · Filed: May 8, 2025 · CIK: 1937993
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Cadrenal Therapeutics filed its Q1 2025 10-Q. Check financials.
AI Summary
Cadrenal Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Delaware with its principal executive offices in Ponte Vedra, Florida, operates in the Pharmaceutical Preparations industry. This filing provides an update on its financial and operational status for the first quarter of 2025.
Why It Matters
This filing provides investors and stakeholders with the latest financial and operational details for Cadrenal Therapeutics, Inc. during the first quarter of 2025.
Risk Assessment
Risk Level: medium — As a 10-Q filing, it contains financial and operational updates for a public company, which inherently carries investment risk.
Key Players & Entities
- Cadrenal Therapeutics, Inc. (company) — Registrant
- March 31, 2025 (date) — Quarterly period end date
- 20250508 (date) — Filing date
- 001-41596 (company) — SEC file number
- 88-0860746 (company) — I.R.S. Employer Identification No.
- 822 A1A North , Suite 306 Ponte Vedra , Florida 32082 (company) — Principal executive offices address
FAQ
What is the reporting period for this 10-Q filing?
The quarterly period ended March 31, 2025.
What is the company's SEC file number?
The company's SEC file number is 001-41596.
Where are Cadrenal Therapeutics, Inc.'s principal executive offices located?
The principal executive offices are located at 822 A1A North, Suite 306, Ponte Vedra, Florida 32082.
What is the Standard Industrial Classification for Cadrenal Therapeutics, Inc.?
The Standard Industrial Classification is Pharmaceutical Preparations [2834].
When was this 10-Q filing submitted?
This filing was submitted on May 8, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Cadrenal Therapeutics, Inc. (CVKD).